Abstract 161P
Background
Chitinase 3-like 1 (CHI3L1) gene codes for the YKL-40 protein. Serum YKL-40 levels are controlled by polymorphisms in the proximal promoter region of CHI3L1 gene. Aim: We aimed to investigate the association of rs880633 (T/C) polymorphism at CHI3L1 gene with serum YKL-40 production and to evaluate the role of this polymorphism as a risk for HCC and its impact on patient’s survival.
Methods
225 subjects were classified into two groups, group I: included 120 HCC patients and group II: included 105 age & gender matched healthy volunteers. Genotyping of (T/C) polymorphism rs880633 at CHI3L1 gene was analyzed using allelic discrimination assay by Real-Time PCR technique and serum YKL-40 level was determined by ELISA.
Results
There was a significant statistical difference as regards genotype frequency of CHI3L1 gene T/C polymorphism between the two studied groups, with increased frequency of CC genotype among HCC patients and increased frequency of TT genotype among the control group. As regards allelic distribution, C allele was significantly more dominant in HCC patients that have increased HCC risk with odds ratio (CI = 95%) of 2.05(1.40 – 2.99) comparing to T allele. Subjects carrying CC genotype had the highest levels serum YKL40 followed by those with TC genotype, while subjects with TT genotype were found to have the lowest serum YKL40. HCC Patient with TT genotype had significantly longer survival rate than those had TC, CC genotypes, Overall survival of HCC patients revealed that both CC and CT genotypes had significantly shorter survival rate than those had TT genotype (P value <0.05).
Conclusions
CHI3L1 gene variants rs880633 might be a candidate risk factor for HCC. Carriers of CC genotype have highest serum YKL40 levels, are associated with criteria of bad prognosis. So, genotyping of (T/C) polymorphism rs880633 at CHI3L1 gene could predict the patient outcome.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Menoufia University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
9P - XRCC1 Arg194Trp, Palb2 T1100T (3300T>G), HMMR V353A, TNF aG308A polymorphisms as diagnostic and prognostic markers of breast cancer in the Kyrgyz ethnic group
Presenter: Aigul Semetei kyzy
Session: Poster display session
Resources:
Abstract
232P - Early Results from the Phase I Study of SY-1365, a Potent and Selective CDK7 inhibitor, in Patients with Ovarian Cancer and Advanced Solid Tumors
Presenter: Debra Richardson
Session: Poster display session
Resources:
Abstract
382P - Drug metabolizing enzymes pharmacogenomic: Biomarkers for improved chemotherapy in head and neck cancer squamous cell carcinoma
Presenter: Sunishtha Bhatia
Session: Poster display session
Resources:
Abstract
401P - Women in oncology: Alarming figures from India
Presenter: Sharada Mailankody
Session: Poster display session
Resources:
Abstract
416P - Multidisciplinary management of sarcomas of the head and neck: An institutional experience
Presenter: Kavitha Jain
Session: Poster display session
Resources:
Abstract
523P - Co-morbilities and survival of patients initially diagnosed with extensive-stage small cell lung cancer: Impact of hypertension, diabetes and chronic hepatitis B viral infection
Presenter: Weigang Xiu
Session: Poster display session
Resources:
Abstract
529P - Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study
Presenter: Roni Gillis
Session: Poster display session
Resources:
Abstract